Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical has announced its approval for the 2025 H Share and A Share Repurchase Plans, aimed at preserving the company’s value. The repurchase plan for H Shares will not exceed 5% of the total, while the A Shares repurchase will involve funds between RMB300 million and RMB600 million. These plans are set to be funded by the company’s own resources or self-raised funds. The move is intended to enhance shareholder value and offers flexibility in managing the company’s capital, with implications for potential future equity incentives or employee share schemes.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in the People’s Republic of China and operates within the pharmaceutical industry. The company focuses on the production, research, and development of pharmaceutical products and healthcare services, with a market presence both domestically and internationally.
YTD Price Performance: -7.95%
Average Trading Volume: 1,184
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $7.83B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.
